ClinicalTrials.gg
RecruitingNCT07124702Updated Nov 19, 2026

Cessation of Dual Use of Cigarettes and E-cigarettes During Pregnancy

An interventional study of Simultaneous cessation intervention and Stepwise cessation intervention in Dual Use of Cigarettes and E-cigarettes, Gestational Weight Gain and Birth-weight-for-gestational-age z Score, sponsored by State University of New York at Buffalo. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by State University of New York at Buffalo · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 288 studies in Vaping with a site in United States — 66 open to participants now, 74 under way, 1 of them phase 3. Vaping · United States.

Planned enrollment
167th of 258
45 · median 71
Started
2025
with 36 others
No phase
206 of 288
39 open now
Primary completion
2027-09
later than 38 of 73 live
Registered
254th of 288
by date

Among the 288 studies in Vaping with a site in United States, this one is the 167th largest by planned enrollment of the 258 interventional ones that give a count, is one of 37 that started in 2025, is one of 206 with no phase, reaches primary completion later than 38 of the 73 other live ones, and was the 254th registered.

Vaping

404 studies on the registry are indexed under Vaping; 97 are open to participants now.

Browse Vaping studies →

Open to participants now

66 of the 288 studies in Vaping with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 288 studies in Vaping with a site in United States, or all of them as a file.
02

Study summary

We propose a randomized controlled trial to develop and evaluate a cessation program with two different strategies for dual users during pregnancy. We plan to enroll 45 pregnant mothers (≤20 gestational weeks) with low household incomes from the Western NY region. To be eligible, they must be currently dual using CCs and nicotine-containing ECs. These mothers will be randomized into one of three groups: 1) simultaneous cessation intervention group (N=15), 2) stepwise cessation intervention group (N=15), and 3) control group (N=15). We hypothesize that nicotine abstinence rates at 8 weeks after randomization will be higher in the intervention groups than in the control group.

Read the detailed description

Study overview. We propose a pilot randomized controlled trial (RCT) to develop and test a cessation program for dual users during pregnancy. We will enroll 45 Western New York pregnant mothers (≤20 weeks gestational age) with low household incomes who are currently dual-using CCs and nicotine-containing ECs. These mothers will be randomized into one of three groups: 1) simultaneous cessation intervention (N=15), 2) stepwise cessation intervention (N=15), and 3) control group (N=15). Both intervention groups will receive a multi-component intervention, including behavior counseling, biomarker feedback, and contingent financial incentives for biochemically verified abstinence. However, the two intervention groups will have different orders of cessation targets: the simultaneous cessation group will target CCs and ECs at the same time, whereas the stepwise cessation group will first target CCs and then target ECs after quitting CCs. The control group will only receive behavior counseling. Mothers will be followed throughout pregnancy until delivery. The primary outcome is nicotine abstinence at 8 weeks after randomization.

Randomization. After the pre-test visit, participants who are still dual using CCs and ECs will be randomized into one of three groups: 1) simultaneous cessation intervention group, 2) stepwise cessation intervention group, and 3) control group. A computer will be used to generate balanced-permuted blocks with a block size of 9 and a 3-3-3 ratio, which can ensure equal numbers of participants across the three groups throughout the project. The study biostatistician will create the sequences a priori and then apply them using a workflow and database software system.

Sample size. Based on the literature and our previous intervention, we estimate the dual-use nicotine abstinence rate at 8 weeks after randomization (the primary maternal outcome) to be 30% in the intervention groups versus 10% in the control group. Accordingly, we need 62 participants per group to detect a significant difference in nicotine abstinence with 80% power at a significance level of 0.05 (Aim 1). Therefore, 15 participants per group for this pilot study should provide a sufficient sample size to test study feasibility, recruitment, and retention and yield preliminary data on intervention efficacy and the magnitude of group differences in health outcomes to support an NIH R01 grant application for a large project.

Statistical analysis. We will first conduct descriptive analyses to determine if transformations are necessary, and then run bivariate analyses. We will compare the distributions of covariates above across the 3 randomized groups. Only the unbalanced covariates that predict smoking/vaping abstinence will be controlled in data analyses. We will use Intention-to-Treat analysis, i.e., including all women as assigned at randomization. Multiple imputations with 20 replicates will be used to impute missing data on outcomes or covariates.36 Sensitivity analysis will be conducted by conservatively assuming participants lost in the follow-up to be current dual users.

We will use Chi-square tests to compare categorical outcomes (e.g., maternal nicotine abstinence rates) and analysis of variance to compare continuous outcomes (e.g., infant birth-weight-for-gestational-age z-score) across groups. Then, we will use multivariable logistic and linear regression models to fit categorical and continuous outcomes, respectively. A propensity score approach will be used to control confounders, including socio-demographics, pregnancy-related characteristics, and other substance use. The model will include group assignment (simultaneous cessation intervention vs. control, stepwise cessation intervention vs. control, or simultaneous vs. stepwise cessation intervention), fidelity of intervention delivery, adherence to intervention, and a propensity score derived from all unbalanced covariates. We will estimate the group differences in nicotine abstinence rates and odds ratios from the regression model.

03

Conditions studied

  • Dual Use of Cigarettes and E-cigarettes
  • Gestational Weight Gain
  • Birth-weight-for-gestational-age z Score

Keywords

  • Randomized Controlled Trial
  • Tobacco use
  • Electronic cigarette
  • Pregnancy
  • Intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Less than 21 weeks pregnant to ensure adequate time for intervention;
  • 18 years or older;
  • Actively using both cigarettes and electronic cigarettes (e-cigarettes);
  • Willing to receive cessation information;
  • Able to read, understand, and speak English;
  • Having a low household income defined as ≤185% of the federal poverty level.

Exclusion criteria

Exclusion Criteria:

  • Teen pregnancy (\<18 y);
  • Unstable housing;
  • Uncontrolled mental health disorders;
  • Non-English speakers.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Simultaneous cessation intervention

    This simultaneous cessation intervention group will target CCs and ECs at the same time. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.

    Behavioral: Simultaneous cessation intervention

  • Experimental
    Stepwise cessation intervention

    This stepwise cessation intervention group will first target CCs and then target ECs after quitting CCs. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.

    Behavioral: Stepwise cessation intervention

  • Active comparator
    Control group

    Participants assigned to the control group will receive behavior counseling only. They will complete the same number of study visits as their counterparts in the intervention groups.

    Behavioral: Behavior counseling only

Interventions

  • BehavioralSimultaneous cessation intervention

    This simultaneous cessation intervention group will target CCs and ECs at the same time. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.

  • BehavioralStepwise cessation intervention

    This stepwise cessation intervention group will first target CCs and then target ECs after quitting CCs. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.

  • BehavioralBehavior counseling only

    Participants assigned to the control group will receive behavior counseling only. They will complete the same number of study visits as their counterparts in the intervention groups.

06

What researchers measure

Primary outcomes

  1. Nicotine abstinence

    Research staff who are blinded to the participant's group assignment will administer a timeline follow-back interview (trained by the PI, Dr. Wen) to assess the participant's recent smoking and vaping history. Based on self-reports, we will classify smoking and vaping status in the past 7 days (7-day point prevalence) prior to the outcome assessment visits at pre-test, 8 weeks after randomization, and at the end of pregnancy. To confirm self-reported complete nicotine abstinence (i.e., abstinence from both ECs and CCs), 5.0 mL of urine samples will be collected at study visits in the 8th week after randomization and at the end of pregnancy (approximately 35 weeks). An HPLC-MS/MS assay will be used as a gold standard test to determine urine cotinine levels.

    Time frame: 8 weeks after randomization, at the end of pregnancy

Secondary outcomes

  1. The time needed to achieve nicotine abstinence

    We define the time needed to achieve nicotine abstinence as the interval between the day of randomization and the first day of complete nicotine abstinence ("not even a puff") without any relapse until birth delivery.

    Time frame: 8 weeks after randomization, at the end of pregnancy

  2. The mother's gestational weight gain

    Total gestational weight gain (GWG) will be calculated as the difference between weight right before delivery and pre-pregnancy weight. Based on 2009 the Institute of Medicine (IOM) guidelines, we will define inadequate GWG as total GWG less than 28, 25, 15, and 11 pounds for underweight (pre-pregnancy BMI\<18.5 kg/ m2), normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9), and obese mothers (BMI ≥30), respectively.

    Time frame: Right before delivery

  3. The infant's birth-weight-forgestational- age z score

    We will obtain the infant's gestational age, clinical measures on weight, length, and head circumference at birth from delivery records. Gestational age will be calculated as the interval between the self-reported last menstrual period and delivery date. We will calculate the infant's birth-weight-for-gestational-age z score and percentile for the same sex and gestational age. SGA will be defined as birth weight below the 10th percentile.

    Time frame: At birth

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Confidentiality reasons.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.

Of 184 non-industry interventional studies with no phase under Vaping, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 23 months is above that.

Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 6 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Sep 2026 → Sep 2027 and completion Mar 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2025
First posted
Aug 15, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Sep 30, 2027was Sep 2026
CompletionEst.
Mar 31, 2028was Mar 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Sep 30, 2027
Nov 19, 2026
Study completion
Mar 31, 2027→Mar 31, 2028
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Sep 30, 2026→Sep 30, 2027
    Study completion Mar 31, 2027→Mar 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07124702
Responsible party
Xiaozhong Wen (Associate Professor, State University of New York at Buffalo) — Principal investigator
First posted
Aug 15, 2025
Start date
Oct 1, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Xiaozhong Wen, PhD
Contact
xiaozhon@buffalo.edu
716-829-6811
Xiaozhong Wen, PhD
principal investigator · State University of New York at Buffalo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion